Literature DB >> 23740186

Explaining fatigue in ANCA-associated vasculitis.

Neil Basu1, Andrew McClean, Lorraine Harper, Esther N Amft, Neeraj Dhaun, Raashid A Luqmani, Mark A Little, David R W Jayne, Oliver Flossmann, John McLaren, Vinod Kumar, Lars P Erwig, David M Reid, Gary J Macfarlane, Gareth T Jones.   

Abstract

OBJECTIVES: To identify the determinants of fatigue among patients with ANCA-associated vasculitis (AAV).
METHODS: A multicentre cross-sectional study was conducted. Subjects fulfilling the European Medicines Agency criteria for granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (Churg-Strauss) were approached according to consecutive clinic attendance and invited to complete a questionnaire assessing fatigue and putative biopsychosocial determinants of this symptom. Concurrently, potential clinical determinants were recorded. Independent associations of fatigue were identified using forward stepwise logistic regression modelling and their overall impact expressed as population attributable risk (PAR).
RESULTS: The majority (74.8%) of participants (n = 410) reported high levels of fatigue that were found to be significantly associated with numerous biopsychosocial and clinical factors. Sleep disturbance [odds ratio (OR) 5.3, 95% CI 2.7, 10.5] and pain (OR 3.8, 95% CI 2.0, 7.3) were the strongest independent associations of fatigue and, on a population level, each was more than twice as important as any other putative determinant (PAR 18.1% and 16.5%, respectively). Female gender (OR 2.1, 95% 1.1, 4.0), elevated CRP (OR 3.7, 95% CI 1.7, 8.1) and the dysfunctional coping strategies of behavioural disengagement (OR 2.4, 95% CI 1.04, 5.6) and denial (OR 2.4, 95% CI 0.9, 6.7) were also independently associated with fatigue.
CONCLUSION: The data suggest that AAV-related fatigue is multifactorial in origin. Sleep disturbance and pain were found to be most important, although inflammation, as measured by CRP, was also associated. This study has identified potentially modifiable determinants that will inform future interventions aimed at alleviating fatigue.

Entities:  

Keywords:  ANCA-associated vasculitis; eosinophilic granulomatosis with polyangiitis; fatigue; granulomatosis with polyangiitis; microscopic polyangiitis

Mesh:

Year:  2013        PMID: 23740186     DOI: 10.1093/rheumatology/ket191

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jan-Di Yun; Junghee Ha; Solah Kim; Hyung Ah Park; Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2019-07-16       Impact factor: 2.980

2.  Birmingham vasculitis activity score and the short form 36-item health survey predict current depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis during the SARS-CoV-2 pandemic.

Authors:  Jan-Di Yun; Joo Hye Lee; Jung Yoon Pyo; Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Z Rheumatol       Date:  2022-06-24       Impact factor: 1.530

3.  Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González; Natasha Alcocer-Castillejos
Journal:  Rheumatol Int       Date:  2017-12-15       Impact factor: 2.631

4.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.

Authors:  Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103

Review 5.  Fatigue in chronic inflammation - a link to pain pathways.

Authors:  Karine Louati; Francis Berenbaum
Journal:  Arthritis Res Ther       Date:  2015-10-05       Impact factor: 5.156

6.  What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population.

Authors:  Elisabeth A B Berg; JulieAnne G McGregor; Madelyn E Burkart; Caroline J Poulton; Yichun Hu; Ronald J Falk; Susan L Hogan
Journal:  J Autoimmune Dis Rheumatol       Date:  2014-11-01

7.  Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Joanna C Robson; Jill Dawson; Peter F Cronholm; Susan Ashdown; Ebony Easley; Katherine S Kellom; Don Gebhart; Georgia Lanier; Nataliya Milman; Jacqueline Peck; Raashid A Luqmani; Judy A Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

Review 8.  Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.

Authors:  Joanna C Robson; David Jayne; Peter A Merkel; Jill Dawson
Journal:  Patient Relat Outcome Meas       Date:  2019-02-08

9.  Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Christina V Golemati; Clio P Mavragani; Sophia Lionaki; Dimitrios Karaiskos; Haralampos M Moutsopoulos
Journal:  Front Psychiatry       Date:  2017-12-15       Impact factor: 4.157

10.  Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study.

Authors:  Lorraine Harper; Matthew David Morgan; Dimitrios Chanouzas; Hollie K Caulfield; Linda Coughlan; Caroline Dean; Kate Fletcher; Fiona Cramp; Sheila Greenfield; Catherine A Hewitt; Natalie J Ives; Sue Jowett; Amanda Daley
Journal:  BMJ Open       Date:  2018-10-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.